Response to nab-paclitaxel and nedaplatin in a heavily-metastatic thymic carcinoma: A case report

Zhan,Ping; Xie,Haiyan; Yu,Li‑Ke

doi:10.3892/ol.2015.2953

Response to nab-paclitaxel and nedaplatin in a heavily-metastatic thymic carcinoma: A case report

Authors:
- Ping Zhan
- Haiyan Xie
- Li‑Ke Yu
View Affiliations

Affiliations: Department of Respiratory Medicine, Nanjing Chest Hospital, Nanjing, Jiangsu, P.R. China
Published online on: February 10, 2015 https://doi.org/10.3892/ol.2015.2953
Pages: 1715-1718

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Metastatic thymic carcinoma is an aggressive cancer that usually responds poorly to multimodal therapies. Although surgical resection is the preferred treatment for patients with advanced or metastatic disease, the clinical prognosis is typically poor. The present study describes a 63‑year‑old patient with thymic carcinoma who underwent a range of antitumor treatments, including surgical resection, post‑operative radiotherapy and post‑operative chemotherapy with several drugs, but ultimately responded to treatment with nab‑paclitaxel (nab‑P) and nedaplatin. Subsequent to six cycles of nab‑P and nedaplatin, the lung and peritoneal metastases decreased in size and the pleural effusion was reduced. To the best of our knowledge, this is the first study to describe the response of an advanced thymic carcinoma to nab‑P chemotherapy.

View Figures

View References

1	Ströbel P, Marx A, Zettl A and Müller-Hermelink HK: Thymoma and thymic carcinoma: an update of the WHO Classification 2004. Surg Today. 35:805–811. 2005. View Article : Google Scholar : PubMed/NCBI
2	Engels EA: Epidemiology of thymoma and associated malignancies. J Thorac Oncol. 5(Suppl 4): S260–S265. 2010. View Article : Google Scholar : PubMed/NCBI
3	No authors listed. Proceedings of the First International Conference on Thymic Malignancies; August 20–21, 2009; Bethesda, Maryland, USA. J Thorac Oncol. 5(Suppl 4): pp. S259–S370. 2010
4	Kondo K and Monden Y: Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan. Ann Thorac Surg. 76:878–885. 2003. View Article : Google Scholar : PubMed/NCBI
5	Masaoka A, Yamakawa Y, Niwa H, et al: Thymectomy and malignancy. Eur J Cardiothorac Surg. 8:251–253. 1994. View Article : Google Scholar : PubMed/NCBI
6	Ströbel P, Bauer A, Puppe B, et al: Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis. J Clin Oncol. 22:1501–1509. 2004. View Article : Google Scholar : PubMed/NCBI
7	Girard N, Mornex F, Van Houtte P, Cordier JF and van Schil P: Thymoma: a focus on current therapeutic management. J Thorac Oncol. 4:119–126. 2009. View Article : Google Scholar
8	Rashid OM, Cassano AD and Takabe K: Thymic neoplasm: a rare disease with a complex clinical presentation. J Thorac Dis. 5:173–183. 2013.PubMed/NCBI
9	NCCN Guidelines on the Treatment of Thymomas and Thymic Carsinomas. http://www.nccn.org/professionals/physician_gls/pdf/thymic.pdf. Accessed May 18, 2014
10	Lemma GL, Lee JW, Aisner SC, et al: Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. J Clin Oncol. 29:2060–2065. 2011. View Article : Google Scholar : PubMed/NCBI
11	Pan CC, Chen PC and Chiang H: KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas. J Pathol. 202:375–381. 2004. View Article : Google Scholar : PubMed/NCBI
12	Suzuki M, Chen H, Shigematsu H, et al: Aberrant methylation: common in thymic carcinomas, rare in thymomas. Oncol Rep. 14:1621–1624. 2005.PubMed/NCBI
13	Girard N, Shen R, Guo T, et al: Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas. Clin Cancer Res. 15:6790–6799. 2009. View Article : Google Scholar : PubMed/NCBI
14	Yoh K, Nishiwaki Y, Ishii G, et al: Mutational status of EGFR and KIT in thymoma and thymic carcinoma. Lung Cancer. 62:316–320. 2008. View Article : Google Scholar : PubMed/NCBI
15	Ströbel P, Bargou R, Wolff A, et al: Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience. Br J Cancer. 103:196–200. 2010. View Article : Google Scholar : PubMed/NCBI
16	Schirosi L, Nannini N, Nicoli D, et al: Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors. Ann Oncol. 23:2409–2414. 2012. View Article : Google Scholar : PubMed/NCBI
17	Bisagni G, Rossi G, Cavazza A, et al: Long lasting response to the multikinase inhibitor bay 43–9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma. J Thorac Oncol. 4:773–775. 2009. View Article : Google Scholar : PubMed/NCBI
18	Li XF, Chen Q, Huang WX and Ye YB: Response to sorafenib in cisplatin-resistant thymic carcinoma: a case report. Med Oncol. 26:157–160. 2009. View Article : Google Scholar
19	Gardner ER, Dahut WL, Scripture CD, et al: Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res. 14:4200–4205. 2008. View Article : Google Scholar : PubMed/NCBI
20	Socinski MA, Langer CJ, Okamoto I, et al: Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer. Ann Oncol. 24:314–321. 2013. View Article : Google Scholar
21	Socinski MA, Bondarenko I, Karaseva NA, et al: Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol. 30:2055–2062. 2012. View Article : Google Scholar : PubMed/NCBI